On March 9, 2022 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, reported the company will make seven oral presentations at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 being held April 8-13, 2022 in New Orleans, Louisiana (Press release, Revolution Medicines, MAR 9, 2022, View Source [SID1234609791]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Four of the company’s oral presentations will be featured in the conference mini-symposium session entitled "Targeting the RAS Oncogene." These presentations will describe recent research findings regarding Revolution Medicines’ broad pipeline of RAS(ON) Inhibitors currently in development, including RMC-6236 (RASMULTI), RMC-6291 (KRASG12C), RMC-9805 (KRASG12D) and RMC-8839 (KRASG13C).
Three additional oral presentations from Revolution Medicines will provide deeper insights into the tri-complex RAS(ON) inhibitor platform. These will highlight the mechanisms underlying this novel inhibitor modality and the broad potential of this platform to target the RAS(ON) form of multiple oncogenic RAS variants and deliver first-in-class therapeutics designed to address the significant unmet needs of patients with RAS-addicted cancers.
Additionally, collaborators of Revolution Medicines will make four separate poster presentations. Three of these describe the activity of the company’s RAS(ON) Inhibitors and/or RAS Companion Inhibitors in preclinical models. A fourth relates to machine-learning digital pathology in support of clinical biomarker strategies.
Details of the planned presentations are as follows:
Revolution Medicines Oral Presentations:
Title: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor
Presenter: Mallika Singh, Ph.D., vice president, translational research
Abstract Number: 3597
Session: Targeting the RAS Oncogene
Date/Time: 2:35 – 2:50 p.m. Central on April 12, 2022
Title: RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers
Presenter: Bob Nichols, Ph.D., project team leader for RMC-6291
Abstract Number: 3595
Session: Targeting the RAS Oncogene
Date/Time: 2:50 – 3:05 p.m. Central on April 12, 2022
Title: RM-036 (RMC-9805), a first-in-class, orally-bioavailable, tri-complex covalent KRASG12D(ON) inhibitor, drives profound anti-tumor activity in KRASG12D mutant tumor models
Presenter: John Knox, Ph.D., senior director, computational chemistry
Abstract Number: 3596
Session: Targeting the RAS Oncogene
Date/Time: 3:05 – 3:20 p.m. Central on April 12, 2022
Title: A first-in-class tri-complex KRASG13C(ON) inhibitor validates therapeutic targeting of KRASG13C and drives tumor regressions in preclinical models
Presenter: Christopher Schulze, Ph.D., associate director, molecular and cellular cancer biology
Abstract Number: 3598
Session: Targeting the RAS Oncogene
Date/Time: 3:20 – 3:35 p.m. Central on April 12, 2022
Title: Discovery and development of RAS(ON) inhibitors beyond KRASG12C
Presenter: Elena S. Koltun, Ph.D., vice president, medicinal chemistry
Session: Chemistry to the Clinic, Part 1 of 3 – Targeting RAS Beyond KRASG12C
Date/Time: 9:00 – 9:20 a.m. Central on April 9, 2022
Title: Translating frontier oncology targets to outsmart cancer
Presenter: Matthew Holderfield, Ph.D., senior director, cancer cell and systems biology
Session: Challenging Drug Targets
Date/Time: 10:20 – 10:40 a.m. Central on April 12, 2022
Title: Pediatric Cancer Drug Discovery: The RAS/MAPK Pathway
Presenter: Clay Gustafson, M.D., Ph.D., senior medical director
Session: Pediatric Cancer Working Group Town Hall Meeting
Date/Time: 6:30 – 8:30 p.m. Central on April 10, 2022
Collaborator Poster Presentations:
Title: Combination of KRASG12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumour immunity
Abstract Number: 4029/8
Session: Molecular Pharmacology
Presentation Time: 9:00 a.m. – 12:30 p.m. Central on April 13, 2022
Title: Effective in vivo treatment of endometrial tumor models with coexistent mutant PI3K and PTEN inactivation with a selective bi-steric mTORC1 kinase inhibitor
Abstract Number: LB089/14
Session: Late-Breaking Research: Experimental and Molecular Therapeutics 1 / Chemistry
Presentation Time: 1:30 – 5:00 p.m. Central on April 11, 2022
Title: Bi-steric mTORC1 inhibitor RMC-6272 synergizes with immune checkpoint inhibitors to induce sustained regression of MYC-driven hepatocellular carcinoma
Abstract Number: 2662/5
Session: Signaling Pathway Inhibitors
Presentation Time: 9:00 a.m. – 12:30 p.m. Central on April 12, 2022
Title: Machine learning models identify histological features that can predict KEAP1 mutations in lung adenocarcinoma
Abstract Number: 5059
Session: Convergence Science and Systems Biology
Presentation Time: 12:00 – 1:00 p.m. Central on April 8, 2022
Additional information on the AACR (Free AACR Whitepaper) Annual Meeting 2022 is available through the AACR (Free AACR Whitepaper) website at: View Source